Although they have also shown better in vitro response of established pancreatic cancer cells using PEGylated gemcitabine as compared to the regular formulation [22], we observed no significant differences between Gem and PEG-Gem in vitro at the level of cancer stem cell content or induction of apoptosis or cell death using xenograft-derived primary cells. The gene discussed is GEM; the disease is pancreatic neoplasm.